Adipotide
also known as CKGGRAKDC-GG-D(KLAKLAK)2, Prohibitin-targeted peptide
Chimeric pro-apoptotic peptide targeting prohibitin-1 (PHB1) on adipose-tissue vasculature endothelium. Composed of a CKGGRAKDC homing domain coupled to a D(KLAKLAK)₂ mitochondrial-disrupting sequence. Induces selective apoptosis of adipose blood vessels, triggering adipocyte involution and weight loss in obese rhesus monkeys and rodent models. No human trials initiated.
At a glance
IV · Systemic · Preclinical Protocols Only
Primary target — Prohibitin-1 (PHB1) on adipose vasculature endothelium [hossen-2013].
Pathway — CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption.
Downstream effect — Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss.
Origin — Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence.
Feedback intact — N/A — Direct apoptotic mechanism, non-hormonal.
| Parameter | Value |
|---|---|
| Animal dose (mouse) | Low dose (not specified in abstract) [hossen-2013]Systemic injection in diet-induced obesity (DIO) models. [hossen-2013] |
| Route | Intravenous (systemic injection) |
| Frequency | Not specified in available data |
| Evidence basis | Preclinical animal models only |
| Human data | None — no clinical trials reported |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Diet-induced obesity mouse models, rhesus monkey preclinical studies
| Outcome | Finding |
|---|---|
| Primary fat target | White adipose tissue (all depots) |
| Mechanism | Vascular apoptosis → adipose blood supply collapse → adipocyte death [hossen-2013] |
| Body weight reduction | Significant reduction in DIO mice [hossen-2013]Absolute values not provided in abstract. |
| Leptin levels | Significant decreaseParallel to adipose mass reduction. |
| Effect on adipocytes | Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages) [hossen-2013] |
| Ectopic fat | Reduction in ectopic fat deposition [hossen-2013]Marker of dysfunctional adipose tissue / metabolic syndrome. |
| Species tested | Obese rhesus monkeys, DIO mice |
| Human translation | Unknown — no clinical trials |
- — Human use — not approved, no clinical safety data
- — Any condition requiring intact adipose-tissue vascularisation
- 01Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
- 02Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice). [hossen-2013]
- 03Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed. [hossen-2013]
- 04Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
Sources
of 49 rendered claims carry a resolvable citation.
- [hossen-2013]Hossen 2013 — A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.
journal, 2013